The Ministry of Food and Drug Safety (MFDS; Minister, Yu-Kyoung Oh) stated that it has granted AstraZeneca Korea’s new breast cancer drug 'Tiroo Cap Tab (capivasertib)' on April 29th.

Capivasertib inhibits the activation of AKT protein, a serine·threonine kinase. Thus, it blocks the intracellular signaling pathway, preventing the survival and proliferation of tumor cells.

This drug can be used in combination with fulvestrant in adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced, or metastatic breast cancer who have one or more mutations in PIK3CA/AKT1/PTEN genes during an endocrine therapy or when the disease progresses after completion, or whe